LDS/Medical Tests/Alpha 1 Antitrypsin Genotyping/Phenotyping

Alpha 1 Antitrypsin Genotyping/Phenotyping

Alpha-1-Antitrypsin or Alpha-1-Antiprotease (α1AT) belong to the serpin superfamily of proteins with a broad spectrum of protease inhibition:

  • destructive neutrophil proteases including elastase, cathepsin G, proteinase 3
  • pancreatic elastase and trypsin, chymotrypsin
  • skin collagenases
  • synovial collagenases

The primary function of α1AT is inhibition of various proteolytic enzymes by forming firm but partially reversible complexes. α1AT is a 52-kDa glycoprotein, synthesized in the liver and to a lesser extent by macrophages and neutrophils. This results in protecting tissues from being harmed by enzymes released from cells when they are injured and inflamed. Alpha-1-Antitrypsin is produced by two copies of a protease inhibitor gene, also known as the SERPINA1 gene. This gene is co-dominant, which means that each SERPINA1 gene copy is responsible for producing half of the body’s Alpha-1-Antitrypsin. If there is a mutation in one or both of the gene copies, then less Alpha-1-Antitrypsin and/or dysfunctional protein is produced. If the production drops to or less than 30% of normal, the affected person will experience a disorder called Alpha-1-Antitrypsin deficiency.

Severe deficiency of Alpha-1-Antitrypsin results in an imbalance between proteinases and inhibitors within the lungs, and also in vascular manifestations, including cervical artery dissection and aneurysms. Without α1AT’s inhibitory effects, enzymes are free to break down elastin, which supports the elasticity of the lungs. This results in complications of the respiratory system including emphysema, chronic obstructive pulmonary disease in adults, and/or liver cirrhosis in adults or children. Therefore, decreased levels or deficiency of Alpha-1-Antitrypsin leads to excessive protease activity and panacinar emphysema in adults or liver disease in children. Cirrhosis of the liver and liver cancer in adults is also associated with the different phenotypes. Decreased levels of Alpha-1-Antitrypsin are also seen in chronic obstructive lung disease, chronic liver diseases, and liver cancers that often lead to liver cirrhosis.

Alpha-1-Antitrypsin is up-regulated during acute phase response to tissue necrosis and inflammatory conditions (acute phase reactant). Serum levels increase in rheumatoid arthritis, bacterial infections, vasculitis, carcinomatosis, and following estrogen level rises after puberty, during pregnancy or in conjunction with contraceptive medication use. Recent publications have also shown that even relatively minor changes, increase or decrease, in the level of Alpha-1-Antitrypsin as an acute phase protein are associated with the development of arterial hypertension and an increased risk of cardiovascular disease.

There are three phenotypes:

  • Pi.MM phenotype which is normal phenotype
  • Pi.MZ or heterozygous phenotype or intermediate deficient
  • Pi.ZZ or homozygous phenotype which results in severe deficiency of Alpha-1-Antitrypsin>Alpha-1-Antitrypsin phenotyping and genotyping is used as a confirmatory testing for patients with Alpha-1-Antitrypsin deficiency and related disorders. Hereditary Alpha-1-Antitrypsin deficiency accounts for 1% to 2% of emphysema cases.
  • To confirm affected or carrier status in individuals with a serum Alpha-1-Antitrypsin concentration less than 100 mg/dL
  • To determine affected or carrier status in individuals with a family history of Alpha-1-Antitrypsin caused by the S or Z alleles
  • Prenatal diagnosis in fetuses whose parents are both known carriers of the Z allele
  • In evaluation of early onset emphysema, especially when a person does not have obvious risk factors such as smoking or exposure to lung irritants (dust and fumes)
  • Alpha-1-Antitrypsin is also ordered to help diagnose the cause of persistent jaundice and other signs of liver dysfunction
  • Used as an aid in evaluation of chronic obstructive lung disease
  • Aids evaluation of neonatal hepatitis
  • Used as confirmatory testing for Alpha-1-Antitrypsin deficiency
  • Used as screening test for relatives of patients with Alpha-1-Antitrypsin deficiency

There are over 40 phenotypes. The most common are M, S and Z:

  • Pi.MM phenotype or normal phenotype, no deficiency
  • Pi.MZ or heterozygous phenotype, intermediate deficient, but no risk of emphysema
  • Pi.ZZ or homozygous phenotype, severe deficiency of Alpha-1-Antitrypsin and high risk of emphysema and liver disease
  • Other phenotypes include:
  • Pi.SS. This phenotype is associated with lower levels of A1AT, but usually no symptoms
  • Pi.SZ. This phenotype results in lower levels of A1AT with a moderately increased risk of emphysema and liver disease
  • Pi.Z/null. Severe deficiency of A1AT and high risk of emphysema and liver disease
  • Pi.null/Pi.null. No A1AT is produced and emphysema occurs, but importantly there is no liver disease since no A1AT accumulates in the liver

A number of factors influence the interpretation of A1A phenotype and genotype testing, among these being DNA polymorphisms, rare allelic variants, protein replacement therapy, acute illness and allogeneic bone marrow transplant. It cannot be emphasized too strongly that serum A1A levels and results of phenotype and genotype testing must be correlated, and if there is a discrepancy additional studies such as DNA sequencing, additional clinical information and isoelectric focusing should be undertaken.

Pi.MM phenotype or normal phenotype
 

 

Isoelectric focusing for phenotyping, Molecular genetic mutation testing (PCR ARMS, Sequencing, RFLP).

Whole Blood EDTA (Lavender), ACD (Yellow) or Heparin (Green).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7 days
  • Frozen: 7 days
Alpha-1-Antitrypsin serum levels, Liver Enzymes, Protein Electrophoresis, Cystic Fibrosis Mutation, Alpha1 anti-protease functional assay
5-7 days after receipt in performing laboratory.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Thorax. 2000 Jul;55(7):614-8. [PMID: 10856323]
  • Respir Med. 2000 Aug;94 Suppl C:S1-2 [PMID: 10954246]
  • Mo Med. 2007 May-Jun;104(3):255-9. PMID: 17619502]
  • Curr Gastroenterol Rep. 2006 Feb;8(1):14-20. [PMID: 16510030]
  • Intern Med. 2004 Mar;43(3):223-6. [PMID: 15098605]
  • Semin Liver Dis. 1998;18(3):217-25. [PMID: 9773422]
  • Alan Wu. Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders; 4 edition (June 13, 2006). ISBN-10: 0721679757.